← All trials
NCT06524947
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2024
- Primary completion
- Mar 28, 2027
- Completion date
- Mar 28, 2027
- First posted
- Jul 29, 2024
- Last posted
- Aug 28, 2024
- Enrollment
- 6600
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
- Government of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.